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Antihypertensive mechanism of diuretic treatment with chiorthalidone.
Complementary roles of sympathetic axis and sodium. Twenty-three
patients with untreated mild to moderate essential hypertension had on
the average an abnormally increased cardiovascular pressor respon-
siveness to exogenous norepinephrine (NE), while plasma and urinary
NE, exchangeable body sodium and blood volume were normal. An
increased pressor responsiveness to angiotensin II in these patients was
associated with a tendency for low plasma renin activity (PRA).
Compared to placebo conditions, treatment with chlorthalidone, 100
mg/day, for 6 weeks significantly decreased blood pressure and ex-
changeable sodium in these hypertensive patients but not in ten normal
subjects; blood volume and heart rate were unchanged in both groups.
Chlorthalidone induced a marked increase in PRA, but only a mild
increase in angiotensin II pressor dose. In contrast, the diuretic caused
a greater increase in NE pressor dose than in plasma NE in the
hypertensive group, thus improving the disturbed relationship between
plasma NE and NE responsiveness in these patients. No significant
modification of plasma NE and NE responsiveness occurred in diuretic-
treated normal subjects. In addition to sodium and the renin-angiotensin
system, the sympathetic regulatory axis seems to be involved in the
antihypertensive mechanism of chlorthalidone. Thiazide-like diuretics
may decrease blood pressure in essential hypertension in part by
lowering an abnormally high cardiovascular NE responsiveness without
causing an equivalent increase in circulating NE.
Mécanisme antihypertenseur du traitement diurétique avec Ia chior.
thalidone. Roles complémentaires de l'axe sympathique et du sodium.
Vingt-trois malades ayant une hypertension artérielle essentielle, non
traitée, benigne a modérée, avaient sur moyenne une augmentation
anormale des réponses pressives cardiovasculaires a Ia noradrénaline
exogène (NE) tandis que Ia NE plasmatique et urinaire, le sodium
echangeable de l'organisme et le volume sanguin étaient normaux. Une
augmentation de Ia réponse pressive a l'angiotensine It chez ces
malades était associée a une tendance a une faible activité refine
plasmatique (PRA). Par comparaison avec les conditions placebos, le
traitement avec de Ia chlorthalidone, 100 mglj, pendant 6 semaines a
significativement diminué Ia pression sanguine et le sodium échangea-
ble chez ces malades hypertensifs, mais non chez dix sujets normaux; le
volume sanguin et le rythme cardiaque étaient inchanges dans les deux
groupes. La chlorthalidone a induit une augmentation marquee de Ia
PRA, mais seulement une augmentation modérée de la dose pressive
d'angiotensine II. Au contraire, le diurétique a entraIné une plus grande
augmentation de Ia dose pressive de NE que de la NE plasmatique dans
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le groupe hypertensif, améliorant ainsi La relation perturbée entre Ia NE
plasmatique et la réponse a la NE chez ces malades. Aucune modifica-
tion significative de Ia NE plasmatique et de la réponse a la NE n'est
survenue chez des sujets normaux traités par Ic diuretique. En plus du
sodium et du système rénine-angiotensine, l'axe regulatoire sympath-
ique semble ètre implique dans le mécanisme antihypertenseur de Ia
chlorthalidone. Les diuretiques voisins des thiazides pourraient dimin-
uer la pression artdrielle dans l'hypertension essentielle en partie en
diminuant une réactivité a la NE cardiovasculaire anormalement haute,
sans entrainer une augmentation equivalente de l'activité adrénergique
nerveuse.
Diuretics have been used as the major antihypertensive drugs
for many years. However, the mechanism underlying their
blood pressure-lowering action is still not completely under-
stood. Diuretics may cause extracellular sodium and fluid
volume depletion. This effect is most pronounced after acute
administration [1]. But following short-term or chronic diuretic
treatment, blood volume tends to be restored toward normal
values [2—41 and only a mild decrease in extracellular fluid
volume is maintained [2, 4—61. Diuretic agents have also been
found to blunt the cardiovascular reactivity to pressor hor-
mones such as angiotensin II [7] or norepinephrine [8—ill.
Nevertheless, such changes must not necessarily result in a net
depressor effect. Decreased pressor sensitivity to angiotensin II
or norepinephrine in diuretic-treated patients could reflect
merely a physiologic adaptation to a concomitant increase in
plasma angiotensin II [7] or norepinephrine [121 levels. In fact,
acute or short-term administration of diuretic agents is well
known to activate the renin-angiotensin system [13, 141.
To our knowledge, data have not been available in the
literature on the relationship between plasma norepinephrine
concentrations and cardiovascular norepinephrine responsive-
ness during diuretic therapy. Previous work by this and another
group suggested that both borderline [15, 161 and established
essential hypertension [12, 15, 17] may be associated with, and
perhaps induced or maintained by, an inappropriately increased
pressor responsiveness to norepinephrine in the presence of
normal or sometimes supernormal plasma norepinephrine lev-
els. Therefore, the present study was undertaken to investigate
the influence of treatment with the standard diuretic-antihyper-
tensive agent, chlorthalidone, on the sympathetic regulatory
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axis in normal subjects and patients with essential hyperten-
sion. In addition, blood volume, exchangeable body sodium,
plasma renin activity, and the cardiovascular pressor respon-
siveness to angiotensin II were also evaluated, allowing a more
integrated approach to the analysis of blood pressure regulation
during diuretic treatment.
Methods
Subjects. Twenty-three hypertensive patients (18 males and 5
females) and ten normal subjects (8 males and 2 females) were
studied. Mean age in the two groups was 47 13 (range, 24 to
65 years) and 35 15 (SD) years (range, 20 to 57 years),
respectively (P < 0.05). The normal subjects were healthy
volunteers, with blood pressure values consistently below 140/
90 mm Hg. Eleven patients had borderline hypertension as
defined by intermittent blood pressure values between 141/91 to
159/94 mm Hg and sometimes below that range [161. Twelve
patients had established essential hypertension as defined by an
average blood pressure greater than 160/95 mm Hg. Secondary
forms of hypertension were excluded by the usual tests. Any
antihypertensive or other drugs were discontinued 4 weeks
before the study. The subjects were instructed to stay on a diet
without added salt and without very salty food. They ingested
approximately 6 to 10 g of sodium per day. Moreover, they
were informed of the purpose and investigative character of the
study and all gave their consent.
Study plan. At first, both groups were given a placebo, I
tablet every morning for 4 weeks. The placebo was then
replaced by the active chlorthalidone, 1 tablet (100 mg) every
morning for 6 weeks. At the end of the placebo and diuretic-
treatment phases, the following studies were performed. Twen-
ty-four-hour urinary sodium, potassium, creatinine, norepi-
nephrine and epinephrine excretion rates, and exchangeable
body sodium were obtained, and plasma sodium and potassium,
hematocrit, plasma and blood volumes, plasma renin activity
(PRA), aldosterone, norepinephrine (NE) and epinephrine lev-
els, blood pressure and pulse rate were determined between 8
and 10A.M. after 1 hr of recumbency, according to our standard
procedure [18, 19]. In addition, the pressor responsiveness to
intravenously infused NE or angiotensin II was tested [20, 211.
Measurements of total plasma NE clearance during norepineph-
rine infusion were made in the supine position [21]. Following
60 mm of a slow intravenous infusion of 5% glucose (6 to 12 ml/
hr by constant-infusion pump), at least five basal blood pressure
values and a blood sample for determination of basal plasma
NE and PRA were obtained. Thereafter, an infusion containing
15 to 30 g/ml of NE in 5% glucose solution was started. NE
was infused stepwise at three to six increasing dose rates,
ranging from 1 to 40 ng/min. Blood pressure was measured
during each infusion rate every 30 to 60 sec until it had
stabilized for at least 5 mm. At two infusion rates, that is, when
increases in mean blood pressure of 10 to 15 and 20 to 40 mm
Hg, respectively, were achieved, blood samples for determina-
tion of plasma NE were withdrawn 10 to 20 mm after starting
the corresponding infusion rate. After an interval of 30 mm with
infusion of only 5% glucose, another blood sample for measure-
ment of PRA and plasma NE was collected and an infusion of
angiotensin II (hypertensin) in 5% glucose was begun. Utilizing
various pump speeds and angiotensin II solutions with concen-
trations ranging from 1.5 to 3 g/ml, the angioten sin dose was
titrated to reach target levels of 5 to 15 and 20 to 30 mm Hg
above the basal diastolic blood pressure.
Techniques. Blood pressure was measured using standard
cuff and sphygmomanometer; each recorded blood pressure
was the mean of three measurements. For determination of the
cardiovascular pressor responsiveness, blood pressure was
registered with an automatic blood pressure recorder (Physio-
metrics SR2). Mean blood pressure was calculated as the sum
of the diastolic (disappearance of sounds) and one third of the
pulse pressure. Plasma and urinary sodium and potassium
concentrations were determined by flame photometer, creati-
nine levels by autoanalyzer, and hematocrit by the microcrit
procedure. Plasma and blood volumes and exchangeable body
sodium were measured by standard isotope dilution methods
using '251-human serum albumin and 24Na, respectively [181.
Results of volumes and exchangeable sodium were expressed
both as the total values measured and as a percentage of the
expected normal value related to body surface area; the latter
approach is based on previous observations in 42 normal
females and 57 normal males and, therefore, also adjusts for
sex-related variations [22]. PRA and aldosterone levels were
measured by radioimmunoassay [23, 24]. Catecholamines (NE,
epinephrine) were determined in plasma by a radioenzymatic
method [25] and in urine by a fluorometric method [26], as
reported previously from this laboratory [19, 20].
Dose-response curves for the relationship between infused
NE or angiotensin II and changes in blood pressure were
plotted on semilogarithmic paper and further analyzed as fol-
lows. A regression line was constructed based on two to three
consecutive data points distributed below and above the level of
a pressor agent-induced increase in mean (norepinephrine) or
diastolic (angiotensin II) blood pressure of 20 mm Hg. The
steepest part of the dose-response curve was chosen for this
regression line because it represents most closely the linear part
of the curve. From these regression lines, two parameters of
pressor responsiveness were derived. These included (I) the
slope of the pressor-response curve; and (2) the pressor dose,
that is, the amount of pressor agent necessary to elevate mean
(norepinephrine) or diastolic blood pressure (angiotensin II) by
20 mm Hg [20, 211.
The total plasma NE clearance (Cl) was calculated [21] by the
formula:
Cl (liter — NE dose per time\mm) corresponding plasma NE
minus basal plasma NE
Statistical analysis. Since natural logarithmic transformation
rather than absolute values followed a Gaussian distribution,
the natural logarithmic transformation of PRA, plasma cate-
cholamine values, and pressor or threshold doses was used for
statistical tests. Differences between study groups or between
placebo and chlorthalidone-treatment conditions were assessed
by two-tailed, unpaired z test or paired t test, respectively.
Results
Clinical and biochemical profile before and following
chiorthalidone administration. At the end of the placebo peri-
od, the 10 normal subjects and 23 hypertensive patients did not
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Table 1. Clinical features and various pressor factors before and following chlorthalidone treatment in normal subjects and patients with
essential hypertension (mean sEM)
Essential hypertension
All
23
151/99 4/3
129/86 3/2d
Heart rate, beats/mm P
C
P
C
P
C
p
C
P
C
67 4 65 4
69 4 67 3
68 3
69 4
17
20
8
7
3
2
10
+ 13
67 3
68 2
l2 II
152 II
56 S6 4
4 3
3 22 10
33 l2
Abbreviations: P, placebo; C, chlorthalidone; N, number of subjects.
a Value is expressed as the percentage of the expected normal value in women or men, respectively 1221.
P < 0.05;
'P < 0.01;
P < 0.001 versus corresponding value under placebo conditions;
P < 0.05 versus normal subjects.
differ significantly in their mean heart rate, plasma sodium,
potassium, PRA, plasma aldosterone, and NE levels as well as
urinary sodium, NE, epinephrine and potassium excretion rates
(Table 1). Plasma epinephrine values tended to be increased
slightly in the patients. Mean body weight, total exchangeable
sodium, and total blood volume also tended to be higher in the
patients, but exchangeable sodium and blood volume related to
body surface area were similar in the normal and hypertensive
groups. When the patients were stratified into 11 with border-
line and 12 with established hypertension (see Methods), the
measured parameters did not differ between these subgroups,
except for a slight decrease in plasma potassium in the patients
with established hypertension.
Following 6 weeks of chlorthalidone treatment, blood pres-
sure was decreased significantly in hypertensive, but not in
normal, subjects (Table 1). Body weight and exchangeable
sodium tended to be decreased slightly in both groups. The
patient subgroups with borderline or established hypertension
responded to chlorthalidone with roughly comparable de-
creases in mean body weight (—1.4 2.0 vs. --1.7 1.2 kg,
respectively) and total exchangeable sodium ( 138 and —96
mEq, respectively); but blood pressure was reduced more
markedly in the subgroup with established hypertension (—10/5
9/7 vs. —34/18 20/12 mm Hg, respectively). Total blood
volume was unchanged in both the normotensive and hyperten-
sive groups.
N
Blood pressure
Treatment Normal subjects Mild Moderate
P 120/75
10
3/2
11
138/88 4/3 164/109
12
5/3
C 122/75 3/1 127/82 4/2c 130/89 5/2
69.6 + 2.9
68.2 3.1
79.5 + 3.7'
78.6 3.9
76.7 3.1
75.1 2.9c
78.1 + 2.4'
76.8 2.4d
121
+ 110
1.6
1.8
336
334
5.1
4.8
2957
2861
100.4
98.1
3008
2870
99.3
95.5
4468
4205
95.5
90.0
148
ll2h
2.2
1.lh
148
134"
2.2
+ 1.7"
227
326
4.5
6.4
P
C
P 2765
C 2740
P 99.7
C 98.4
P 4114
C 4260
P 93.6
C 96.6
P 138.2
C 137.7
P 4.06±
C 3.21±
P 2.0
C 6.5±
P 5.5
C 14.9±
P 22.1
C 26.0±
P 2.5 +
C 3.4±
Body weight, kg
Exchangeable sodium
Total, mmoles
Related to body surface area,
%a
Blood volume
Total, ml
Related to body surface area,
%a
Plasma sodium, mmoles/liter
Potassium, mmo!es/liter
Renin activity, ng/ml/hr
Aldosterone, ng/dl
Norepinephrine, ng/dl
Epinephrine, ng/dl
Urinary sodium, mmoles/24 hr
Potassium, mmoles 24 hr
Epinephrine, p.glg creatinine
Norepinephrine, p.g/g
creatinine
4387 301
298
2X6
99.8
96.8
442
436
94.8
94.9
99
85'
1.5
1.0'
185
220
3.0
4.l
4511
94.2
99.5
307
4.1
5.1
0.8 137.4 0.4 138.0 0.9 l3'.7 0.5
0.8 136.6 0.5 136.8 0.8" 13(.7 0.4"
0.08 4.06 0.10 3.78 0.07' .92 0.07
0.11" 3.29 0.19" 3.05 0.09" .l9 0.10"
0.3 1.1 0.3' 1.2 0.2 .3 0.2
1.1" 4.4 1.1' 7.0 2.1" .8 l.2d
1.3 4.9 1.4 5.7 1.3 .2 1.0
1.6' 8.9 2.0' 9.9 1.9' ".4 1.4"'
3.9 29.6 5.9 23.5 3.1 2.3 3.3
2.3 34.5 8.5 30.6 4.6 32.5 4.6
0.4 4.0 0.7 3.9 0.8 ..9 0.5'
0.6 3.9 0.8 3.6 0.8 .3.8 0.6
140 13 116 16 138
192 21" 146 IS 158
69 7 55 6 56
90 5h 72 6" 62
4 2 3 1 4
4 3 3 2 3
22 7 26 11 26
36 12' 29 + 10 37
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Chiorthalidone distinctly decreased plasma potassium and
increased plasma renin activity three- to fourfold. These effects
were similar in the normal subjects and hypertensive patients,
indicating an equally good compliance with chlorthalidone
treatment in both groups. Plasma aldosterone levels were also
increased but this change reached statistical significance in the
normal subjects only.
Heart rate and plasma or urinary epinephrine levels were
unchanged, while plasma and urinary NE values tended to be
increased only slightly in the normal and hypertensive subjects.
Cardiovascular pressor responsiveness before and following
diuretic administration. Under placebo conditions, supine PRA
measured immediately before angiotensin II infusion as well as
the angiotensin II pressor dose was significantly lower in
hypertensive than in normal subjects (Table 2). Following 6
weeks of chlorthalidone, a marked increase in pre-infusion PRA
and a mild increase in angiotensin II pressor dose were noted.
Increases in pre-infusion PRA and angiotensin II pressor dose
tended to be more pronounced in hypertensive patients (+ 345%
and +58%, respectively) than in normal subjects (+ 132% and
30%). No significant correlation was observed (1) between
chlorthalidone-induced increases in angiotensin II pressor dose
and concomitant changes in PRA (r =
—0.17) or (2) between
these variations in angiotensin pressor dose or PRA and the age
of the subjects.
Supine pre-infusion plasma NE was similar in normal and
hypertensive groups or subgroups when measured under place-
bo conditions; however, the NE pressor dose was significantly
lower in the patients (Table 2). The NE pressor dose was also
significantly decreased (P <0.05) in subgroups of patients with
borderline (N = 6) or established (N = 7) hypertension matched
for body weight with an equal number of normal subjects (94
5 vs. 174 81 ng/kg/min, and 66 31 vs. 170 86 ng/kg!min).
There was no significant correlation between age and pre-
infusion plasma NE or NE pressor dose in the normal and
hypertensive subjects (r = 0.21 and —0.20, respectively). NE
pressor dose tended to correlate positively with pre-infusion
plasma NE in the normal or hypertensive groups analyzed
separately (r = 0.38 and 0.27; statistically not significant).
Following chlorthalidone treatment, pre-infusion plasma NE
and NE pressor dose were increased significantly in the hyper-
tensive patients, but not in the normal subjects. In contrast to
the pattern of PRA and angiotensin II pressor dose, the
chlorthalidone-induced increases in NE pressor dose exceeded
those in plasma NE, particularly in the patients with established
hypertension (+ 102 vs. +45%). Thus, in the hypertensive
patients, the relationship between NE pressor dose and pre-
infusion plasma NE was shifted toward a more normal value
(Fig. 1). The chlorthalidone-induced changes in NE pressor
dose did not correlate with concomitant variations in pre-
infusion plasma NE (r = —0.25 to —0.02) or exchangeable
sodium (r = —0.25 to —0.12). There was also no significant
relationship between chiorthalidone-induced variations in NE
pressor dose and the age of the normal or hypertensive subjects
(r = —0.08 to —0.07).
The total plasma NE clearance measured during norepineph-
rifle infusion did not differ between normal and hypertensive
groups or subgroups under placebo conditions and was un-
changed following chlorthalidone treatment (Table 2).
To obtain an estimate of the baroreflex response, variations
Hypertension
Borderline Established
I I I I I
15 25 40 15 25 40 15 25 40
Pre-infusion plasma norepinephrine, ng/dI
Fig. 1. Relationship between norepinephrine pre,ssor dose and basal
(pre-infusion) plasma norepinephrine concentration before (open sym-
bols) and following (closed symbols) treatment with chiorthalidone in
normal and hypertensive subjects (mean values 5EM).
in heart rate during the NE-pressor infusion were also assessed.
Mean heart rate before the start of NE-infusion did not differ
significantly between the normal and hypertensive groups ei-
ther in the untreated state (67 10 vs. 67 12 beats/mm) or
following chlorthalidone-treatment (68 10 vs. 63 10 beats!
mm). In the untreated state, NE-pressor infusion in the normal
and hypertensive subjects caused comparable increases in
mean blood pressure (+29 5 vs. +32 12 mm Hg) and
decreases in heart rate (—14 9 vs. —13 8 beats/mm; or —21
vs. —19%). In the chlorthalidone-treated normal subjects, the
pressure rise during NE-infusion averaged +27 9 mm Hg and
the concomitant decrease in heart rate —9 4 beats/mm
(—13%); both values did not differ significantly from the un-
treated state. In chlorthalidone-treated hypertensive patients,
the NE-induced pressure rise (+24 7 mm Hg) and decrease in
heart rate (—4 8 beats/mm; —6%) tended both to be slightly
lower than in the untreated state (P < 0.05 and < 0.005,
respectively).
Discussion
Under placebo conditions, total exchangeable sodium and
blood volume were both normal in our patients with benign
essential hypertension. These body constituents are age-inde-
pendent in normal subjects [18, 22] while exchangeable sodium
tends to be subnormal in young hypertensives [27]. Variations
in age within the range of our normal or hypertensive subjects
cannot conceal a true difference between the two study groups
[27]. Six weeks of treatment with chlorthalidone in our normal
or hypertensive subjects was associated with a comparable mild
reduction in body weight (—1.4 and —1.3 kg, respectively) and a
tendency for a slight decrease in exchangeable sodium; blood
volume on the other hand was unchanged in both groups. A
limited sensitivity of the radioisotope dilution technique has to
be considered, but small decreases in body sodium induced by a
low-sodium diet were documented accurately by the estimation
of exchangeable sodium [281. The presence of normovolemia
despite mild body sodium depletion in the hypertensive group is
compatible with the reported association of an unaltered circu-
latory volume with a decreased extracellular fluid volume,
Normal
sublects
300—
0
200—
E)
ii.c 100—
a
a,
0z
50
Abbreviations: P, placebo; C, chlorthalidone; N, number of subjects.
a P < 0.05.
P < 0.01.
P < 0.001 versus corresponding value under placebo conditions.
d p < 0.05 versus corresponding value in normal subjects.
following long-term thiazide therapy [2, 4]. A distinct reduction
in blood volume occurs following acute administration of di-
uretics, but intravascular volume repletion with dextran failed
to completely reverse the antihypertensive effect of thiazides
even at this stage [111. Body sodium and/or extracellular fluid
volume may be more important determinants of the blood
pressure-lowering effect of thiazides, since their antihyperten-
sive efficacy was abolished by high salt intake or saline-infusion
[11, 29]. Nevertheless, the absence of a significant correlation
between the chlorthalidone-induced changes in body weight or
in exchangeable sodium and blood pressure in our normal and
hypertensive subjects is consistent with an important role of
additional mechanisms.
Blood pressure depends not only on absolute quantities of
pressor factors, but is co-determined by the responsiveness of
the cardiovascular system. Under physiological conditions,
pressor responses to angiotensin II or NE are inversely related
to the blood levels of PRA, angiotensin II or NE, respectively
[12, 15, 30, 31]. This adjustment may be important for blood
pressure homeostasis.
In the untreated state PRA and angiotensin II pressor dose
tended to be lower in our hypertensive than in normal subjects,
as expected [7, 16, 19, 30—321; the slightly higher age in the
former group may also have favored this constellation [14, 19,
33]. Nevertheless, percentage increases in PRA and angiotensin
II pressor dose which occurred during chiorthalidone-treatment
were not related to the age and rather more pronounced in the
hypertensive than in the normal group. Diuretics may stimulate
renin release through the renal baroreceptor mechanism, in-
creased renal prostaglandin production, a signal related to
tubular handling of sodium and/or chloride, and possibly also as
a secondary consequence of induced hypokaleniia [34—37];
chiorthalidone caused similar decreases in plasma potassium in
the two study groups, but it is possible that the associated
reduction in systemic arterial pressure may have contributed to
renin-activation in the hypertensive patients [36]. Most relevant
for the problem under discussion is the observation of consis-
tently greater percentage increases in PRA (+ 132% in the
normal, +345% in the hypertensive group) than in angiotensin
II pressor dose (+30 and +50% only). Considering that pressor
effects of infused angiotensin II correlate with the logarithmic
rather than the absolute value of the dose [30, 311, one can
assume, therefore, that during chlorthalidone-therapy a hyper-
tensive influence from renin stimulation was balanced out at
least in part by a depressor influence from the blunted cardio-
vascular angiotensin responsiveness. Plasma angiotensin II
rather than PRA is the critical factor in this relationship. Thus,
it is important to note that the ratio between the two compo-
nents was similar before and after short-term thiazide treatment
in both normal and hypertensive subjects [381. In fact, pharma-
cologic studies with competitive angiotensin II inhibition indi-
cated that marked increases in PRA and plasma angiotensin II
without equivalent reduction in angiotensin II pressor response
during diuretic therapy may result in a mild net pressor influ-
ence, and, therefore, an increased blood pressure dependence
on angiotensin II [391.
The sympathetic regulatory axis in our patients with essential
hypertension under placebo conditions was characterized by an
abnormally increased cardiovascular responsiveness to NE in
the presence of normal basal plasma NE concentrations and
clearance values, urinary NE and epinephrine excretion rates
and mildly increased plasma epinephrine levels, as noted previ-
ously [12, 15, 17, 19, 21, 40, 41]. Chlorthalidone-treatment in
these patients had no influence on epinephrine values. Howev-
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Table 2. Cardiovascular pressor responsiveness before and following chlorthalidone treatment in normal subjects and essential hypertension
(mean SD)
Treatment
Normal
subjects
Essential hypertension
Mild Moderate All
10 11 12 23N
Angiotensin II — infusion
Pre-infusion plasma renin activity,
nglml/hr
Angiotensin Il-pressor dose,
nglkg/min
Slope
P
C
P
C
P
C
2.8 ÷ 0.5
6.5 1.2'
15.8 2.5
20.5 4.2
13 212±1
Norepinephrine — infusion
Pre-infusion plasma
norepinephrine, nR/dl
Norepinephrine-pressor dose,
ng/kg/min
Slope
P
C
P
C
P
C
24.7 2.6
23.1 2.5
172 22
200 26
18 2203
Total plasma norepinephrine
clearance, liter/mm
P
C
4.0 0.5
5.7 0.7
1.3 0.3 1.0 0.3d 1.1 0.2'
5.7 0.7 4.1 0.6" 4.9 0.5
7.9 0.7k' 9.3 1.8" 8.5 0.9'
15.4 1.8' 11.6 1.6" 13.4 1.1"
10 II 10
1 1
22.2 4.8 22.7 3.1 22.5 2.3
28.5 5.1" 33.0 34d.h 31.0 55""
94 16" 102 18" 98 10"
139 15"" 206 31" 173 17"
16 IS ÷2 15
18 13 15
4.9 0.6 4.2 0.3 4.5 0.3
4.8 0.7 3.7 0.3 4.3 0.4
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er, it tended to restore the disturbed relationship between NE
pressor response and basal plasma NE toward a more normal
state. Contrasting with the more pronounced effect of chiorthal-
idone on PRA than on angiotensin II pressor dose, our patients
with established hypertension responded with a marked in-
crease in NE pressor dose (about + 100%) and a milder varia-
tion in basal plasma NE (+ 45%) or urinary NE (+ 42%).
Considering that pressor effects of NE correlate also with the
logarithmic rather than absolute values [12, 20, 21], such a slight
raise in peripheral free NE could not antagonize fully the
depressor influence from the blunted cardiovascular NE re-
sponsiveness. In our normal subjects, both NE responsiveness
and plasma NE were not changed consistently following
chlorthalidone-treatment. Thus, compared with PRA catechol-
amine levels appear to be much less responsive to short-term
diuretic treatment. Plasma catecholamine levels are difficult to
assess. Mild variations in plasma NE during chlorthalidone-
treatment could reflect parallel changes in sympathetic outflow
or inverse changes in the clearance rate of NE. A contribution
of the latter factor appears indeed possible from our data (Table
2). There are presently no methods available to measure NE
concentrations in the synaptic cleft, but it is generally accepted
that the heart rate is a sensitive biologic index of changes in
adrenergic activity. Therefore, the unaltered heart rates during
diuretic treatment in this and many previous studies provide a
further argument against a relevant increase in adrenergic tone.
This conclusion is supported by another study from our
laboratory. Using a protocol design which was similar to that in
the present study, treatment of hypertensive patients with the
new diuretic agent indapamide also improved the initially
abnormal NE pressor responsiveness without causing a signifi-
cant change in plasma NE or heart rate; decreases in blood
pressure correlated significantly (r = —0.62, P < 0.05) with
changes in NE pressor dose [421. Hypertensive and normal
subjects were approximately age-matched in the latter investi-
gation [421. Moreover, the slight difference in mean age be-
tween our chlorthalidone-treated normal and hypertensive
groups should not affect the interpretation since exaggerated
NE pressor responses in untreated essential hypertension and
their improvement following diuretic treatment were not related
to the age of the present and previously studied [33, 421
patients.
These modifications in NE responsiveness are probably not
unspecific consequences of variations in basal blood pressure.
Arguments supporting this notion include (1) parallel changes in
digital vascular reactivity in untreated [431 and diuretic-treated
[10] essential hypertension; and (2) exaggerated vascular sensi-
tivity already at the stage of prehypertension, for example, in
normotensive offspring of hypertensive families [441, as con-
trasting with (3) appropriate angiotensin II pressor response
relative to concomitant PRA or angiotensin II levels in most
patients with untreated established essential hypertension [12,
30, 31, 331. Exaggerated NE pressor responses in the untreated
state and their restoration toward normal values in our hyper-
tensive patients also could not be explained by variations in the
responsiveness of the baroreflex. Thus, the NE-induced rise in
blood pressure elicited similar decreases in heart rate in the
untreated normal and hypertensive groups; and the findings
following chlorthalidone-treatment were even consistent with
the possibility of a slightly diminished heart rate response,
particularly in the hypertensive group. However, a tendency for
a blunted responsiveness of the baroreflex following a diuretic
treatment should have antagonized rather than favored the
observed decrease in NE pressor responses in these patients.
An improvement of the cardiovascular NE responsiveness in
essential hypertension may be a characteristic effect of certain
diuretics rather than nonpharmacologic sodium depletion. In
fact, dietary sodium restriction did not modify NE pressor
reactivity [45, 46], although plasma NE concentrations tend to
be distinctly increased under this condition [47]. Nevertheless,
pressor responses to NE or angiotensin II may be different in
the general circulation and in regional vascular beds.
It appears possible that mild extracellular and/or intracellular
depletion may mediate the beneficial effect of chlorthalidone or
certain other diuretics [42] on cardiovascular NE responsive-
ness in essential hypertension. In fact, increased intracellular
sodium content has been incriminated as an important mecha-
nism in the pathogenesis of essential hypertension [48]. Other
potential but similarly speculative mechanisms would be a
stimulation of vasodilator prostaglandin I (PGI) [49] or kinins
[50]. PGI may blunt the vasoconstrictor action of pressor
hormones and is a potent stimulator of renin release [37, 51];
these actions resemble also our main findings during treatment
with chlorthalidone or indapamide [42]. Whatever the exact
underlying mechanism, it is concluded that thiazide-like diuret-
ics may decrease blood pressure in essential hypertension, at
least in part, by lowering an abnormally high NE pressor
reactivity without causing an equivalent increase in adrenergic
nervous activity.
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